Effects of the incorporation of IBTM beta-turn mimetics into the dipeptoid CCK(1) receptor agonist PD 170292.
Replacement of the 2-Adoc-D-alphaMeTrp residue in the non-selective CCK(1) receptor agonist PD 170292 by the Z-(2R,5R,11bS)-IBTM skeleton, able to fix a type II beta-turn-like conformation, led to a conformationally restricted dipeptoid analogue, namely 3a, which exhibited a notable increase in the CCK(1) selectivity and antagonist properties.
Martín-Martínez
Mercedes
M
Instituto de Química Médica (CSIC), Juan de la Cierva 3, 28006 Madrid, Spain.
Latorre
Miriam
M
García-López
M Teresa
MT
Cenarruzabeitia
Edurne
E
Del Río
Joaquín
J
González-Muñiz
Rosario
R
D000218:Adamantane / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D000818:Animals; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D002956:Citrulline / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D018716:Molecular Mimicry; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011949:Receptors, Cholecystokinin / Q000819:agonists*
C414945:PD 170292; D011949:Receptors, Cholecystokinin; D002956:Citrulline; D000218:Adamantane